Sidley-Led Cytomx Seeks $106M IPO To Fund Cancer Drugs
Venture capital-backed biotech Cytomx Therapeutics Inc. on Monday set terms for an initial public offering, advised by Sidley Austin LLP, that could raise $106 million to develop its cancer immunotherapy drugs, making...To view the full article, register now.
Already a subscriber? Click here to view full article